scholarly journals Antenatal Betamethasone for Women at Risk for Late Preterm Delivery

2016 ◽  
Vol 71 (8) ◽  
pp. 453-455 ◽  
Author(s):  
Cynthia Gyamfi-Bannerman ◽  
Elizabeth A. Thom ◽  
Sean C. Blackwell ◽  
Alan T. N. Tita ◽  
Uma M. Reddy ◽  
...  
2019 ◽  
Vol 173 (5) ◽  
pp. 462 ◽  
Author(s):  
Cynthia Gyamfi-Bannerman ◽  
John A. F. Zupancic ◽  
Grecio Sandoval ◽  
William A. Grobman ◽  
Sean C. Blackwell ◽  
...  

Author(s):  
Cynthia Gyamfi-Bannerman ◽  
Kathleen A. Jablonski ◽  
Sean C. Blackwell ◽  
Alan T. N. Tita ◽  
Uma M. Reddy ◽  
...  

Objective In the antenatal late preterm steroids (ALPS) trial betamethasone significantly decreased short-term neonatal respiratory morbidity but increased the risk of neonatal hypoglycemia, diagnosed only categorically (<40 mg/dL). We sought to better characterize the nature, duration, and treatment for hypoglycemia. Study Design Secondary analysis of infants from ALPS, a multicenter trial randomizing women at risk for late preterm delivery to betamethasone or placebo. This study was a reabstraction of all available charts from the parent trial, all of which were requested. Unreviewed charts included those lost to follow-up or from sites not participating in the reabstraction. Duration of hypoglycemia (<40 mg/dL), lowest value and treatment, if any, were assessed by group. Measures of association and regression models were used where appropriate. Results Of 2,831 randomized, 2,609 (92.2%) were included. There were 387 (29.3%) and 223 (17.3%) with hypoglycemia in the betamethasone and placebo groups, respectively (relative risk [RR]: 1.69, 95% confidence interval [CI]: 1.46–1.96). Hypoglycemia generally occurred in the first 24 hours in both groups: 374/385 (97.1%) in the betamethasone group and 214/222 (96.4%) in the placebo group (p = 0.63). Of 387 neonates with hypoglycemia in the betamethasone group, 132 (34.1%) received treatment, while 73/223 (32.7%) received treatment in placebo group (p = 0.73). The lowest recorded blood sugar was similar between groups. Most hypoglycemia resolved by 24 hours in both (93.0 vs. 89.3% in the betamethasone and placebo groups, respectively, p = 0.18). Among infants with hypoglycemia in the first 24 hours, the time to resolution was shorter in the betamethasone group (2.80 [interquartile range: 2.03–7.03) vs. 3.74 (interquartile range: 2.15–15.08) hours; p = 0.002]. Persistence for >72 hours was rare and similar in both groups, nine (2.4%, betamethasone) and four (1.9%, placebo, p = 0.18). Conclusion In this cohort, hypoglycemia was transient and most received no treatment, with a quicker resolution in the betamethasone group. Prolonged hypoglycemia was uncommon irrespective of steroid exposure. Key Points


2016 ◽  
Vol 374 (14) ◽  
pp. 1311-1320 ◽  
Author(s):  
Cynthia Gyamfi-Bannerman ◽  
Elizabeth A. Thom ◽  
Sean C. Blackwell ◽  
Alan T.N. Tita ◽  
Uma M. Reddy ◽  
...  

2017 ◽  
Vol 106 (10) ◽  
pp. 1708-1708 ◽  
Author(s):  
Hannah R. Canty ◽  
Stephanie Dukhovny ◽  
Jamie B. Warren

2019 ◽  
Vol 220 (1) ◽  
pp. S310-S311
Author(s):  
Morgen S. Doty ◽  
Han-Yang Chen ◽  
Suneet P. Chauhan ◽  
Baha M. Sibai

Sign in / Sign up

Export Citation Format

Share Document